Episode Summary
Executive Summary: The episode follows Ben Lamm, CEO of Colossal, on the company’s moonshot to de-extinct species such as the woolly mammoth, thylacine, and dodo, while also building spillover technologies for conservation and human health. The conversation covers the science, funding, ethics, timelines, artificial wombs, and the leadership/capital required to turn a radical idea into a credible biotech company.
Main Topics: Colossal’s de-extinction mission (Priority: 5/5): Lamm frames Colossal as the world’s first de-extinction company, aiming to restore extinct species and develop enabling technologies for conservation and healthcare. How mammoth de-extinction works (Priority: 5/5): The discussion explains that Colossal is not cloning mammoths but editing Asian elephant genomes using mammoth-associated genes tied to cold-tolerance and visible mammoth traits. Company-building and fundraising (Priority: 5/5): Lamm details how he raised capital, built a team, and gained credibility despite lacking a biology background, emphasizing founder conviction and systems thinking. Environmental rationale and conservation impact (Priority: 4/5): The mammoth is positioned as a climate and ecosystem intervention for the Arctic tundra, with broader applications for conservation and biodiversity restoration. Pipeline species and timelines (Priority: 4/5): Beyond the mammoth, Colossal is working on the thylacine and dodo, with differing technical challenges, gestation periods, and development timelines. Artificial wombs and ex utero development (Priority: 4/5): Lamm argues that artificial womb technology may become one of Colossal’s most consequential outputs, enabling scalable gestation of endangered or de-extinct animals. Ethics, public scrutiny, and open sourcing (Priority: 3/5): The conversation addresses concerns about playing God, misuse of gene-editing tools, and what technologies should be open-sourced versus withheld.
Key Arguments: De-extinction is not cloning; it is targeted editing of lost genes to recreate extinct traits in a close living relative. The woolly mammoth project is tractable because the Asian elephant is genetically very close to the mammoth, with only a small fraction of relevant differences. A founder with strong systems thinking, fundraising ability, and team-building skill can unlock moonshots even without domain expertise. Colossal’s work has dual value: the direct goal of de-extinction and the creation of technologies that can be spun out commercially. The mammoth may help restore Arctic grasslands and reduce thawing by influencing vegetation, snow packing, and carbon/methane dynamics. Artificial wombs could have even greater long-term impact than de-extinction by enabling scalable conservation breeding and rewilding. Ethical risks are real, but the answer is transparency, informed critique, collaboration with governments, and selective open sourcing rather than inaction.
Data Points: Capital raised: $225 million - Total funding Colossal has raised to date Post-money valuation: around $1.5 billion - Current valuation described near the beginning of the episode Post-money valuation: around $1 billion - Later mention in the conversation when discussing current valuation Company headcount: 112 full-time employees - Current workforce at Colossal Scientific workforce share: about 90% scientists - Most employees are scientific staff Scientific advisors: 60 advisors - External advisors supporting the company Postdocs funded: 30 postdocs worldwide - Researchers supported in advisors’ labs Labs: 4 labs - Colossal’s operating lab footprint, including one in Australia Mammoth genome similarity: 99.6% - Asian elephant is the closest living relative to the woolly mammoth Mammoth genome inputs: 54 mammoth genomes - Used to build the mammoth reference genome Candidate mammoth edits: about 60-65 genes - Current gene list being edited for mammoth traits Mammoth edits completed: about 20 genes - Genes already edited and under functional testing Mammoth timeline: first calves by early 2028 - Target timeline for the first mammoth calves Gestation length: 22 months - Elephant gestation creates the main bottleneck for mammoth birth Thylacine gestation length: 13.5 days - Marsupial gestation noted as far shorter than elephants Dodo gestation length: about 30 days - Expected developmental timeline for the avian project Ground temperature reduction: up to 8 degrees - Reported impact from Pleistocene Park experiments with rewilding tundra Arctic carbon stored: about 1.6 trillion metric tons - Carbon/methane stock in permafrost discussed as climate risk Mammoth/Arctic methane risk: about 30 times worse - Methane’s relative impact versus atmospheric CO2 in the discussion Cloning efficiency improvement: over 25x - Upcoming breakthrough claimed for cloning/IVF efficiency Software spin-out funding: $30 million - Funding raised for FormBio, a Colossal spin-out FormBio ARR: mid-seven figures - Early revenue traction of the spin-out software company Government contract size: one eight-figure and one separate nine-figure contract - Large international deals under discussion for conservation applications Thylacine extinction year: 1936 - The Tasmanian tiger went extinct in Tasmania in 1936 Dodo last widely accepted sighting: 1662 - Historic extinction reference for the dodo Human genome sequencing cost/time: about $200 and 7 hours - Compared against earlier expensive sequencing era
Pivotal Quotes: "We’re not trying to clone these animals. We are de-extincting lost genes that produce these physical attributes that no longer exist in that species." — Ben Lamm: Explaining the technical distinction between cloning and Colossal’s gene-editing approach "This is the difference that the right CEO and entrepreneur can make for a moonshot." — Host: Reflecting on Lamm’s role in turning a speculative idea into a funded company "I think I’m insatiably curious, right? And I like to learn." — Ben Lamm: Lamm describing why he was able to enter a field outside his original expertise
Implications: The episode suggests moonshot biotech can be financed and executed when science, storytelling, and systems leadership align. If successful, Colossal could reshape conservation, create platform technologies, and normalize de-extinction as a serious engineering discipline.